Clonal hematopoiesis of indeterminate potential

Also called CHIP

There are 685 papers on clonal hematopoiesis of indeterminate potential in aging research: 10 trials and 281 observational studies in people, 50 in animals, 12 in cells, 305 reviews. The newest story, Nov 19, 2026: “Gene mutations linked to heart rhythm risk in blood cancers”.

Biomarker

685 papers study it30 more mention it607 findings

MeSH

98 new papers in 30 daysSee all 715 papers on clonal hematopoiesis of indeterminate potential

“CHIP was not associated with increased risk of MACEs at 2% to 10% VAF (adjusted hazard ratio [aHR], 0.84, 95% CI, 0.68-1.03; P = .09)”
Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of AspirinJAMA cardiology2025doi:10.1001/jamacardio.2025.3756
  • Human trial10
  • Humans281
  • Animals50
  • Cells12
  • In silico18

Interventions

12

Senolytics

downin mice2

2 studies
  1. Senolytics decrease clonal hematopoiesis of indeterminate potential in mice (genetic or pharmacological depletion of senescent non-haematopoietic cells).

    “genetic or pharmacological depletion of senescent non-haematopoietic cells reduces CH burden and delays progression towards myeloid neoplasia in mice”

    Reviewgenetic or pharmacological depletion of senescent non-haematopoietic cellsbone marrow

    Clearing senescent niche cells limits clonal hematopoiesis in mice

    Cancer research

  2. Senolytics decrease clonal hematopoiesis of indeterminate potential in DNMT3A-mutant clonal haematopoiesis.

    “Genetic or pharmacological depletion of senescent non-haematopoietic cells reduces the burden of CH and delays progression to myeloid neoplasia.”

    Animalsin DNMT3A-mutant clonal haematopoiesis

    Bone marrow changes favor mutant blood cells in mice

    Nature cell biology

More on Senolytics

Immunosuppressive therapy

upin humans1

1 study
  1. Immunosuppressive therapy is linked with higher clonal hematopoiesis of indeterminate potential in humans (aplastic anemia) (41% vs 22%).

    “somatic mutations were detected in 53 patients (22%) at baseline and 97 (41%) after IST.”

    Humansaplastic anemiabone marrown = 237

    Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy

    Leukemia

More on Immunosuppressive therapy

Allogeneic hematopoietic stem cell transplantation

upin humans1

1 study
  1. Allogeneic hematopoietic stem cell transplantation is linked with higher clonal hematopoiesis of indeterminate potential in recipients with SCD.

    “After HCT, the proportion of recipients with SCD with CH increased, driven primarily by mutations in DNMT3A/TET2 and TP53”

    Humansin recipients with SCDnonmyeloablative transplantwhole bloodn = 98

    Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease

    Blood

More on Allogeneic hematopoietic stem cell transplantation

Statins

no changein humans1OR 1.05

1 study
  1. Statins were not clearly linked with clonal hematopoiesis of indeterminate potential in humans (TET2-mutant) (OR=1.05 (95% CI 0.97-1.14)).

    “driven primarily by associations with DNMT3A R882-mutant (OR=0.78; 95% CI:0.66-0.92; P=0.003), but not TET2-mutant CH (OR=1.05; 95% CI:0.97-1.14; P=0.20).”

    HumansTET2-mutantn = 416,118

    Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis

    medRxiv : the preprint server for health sciencesPreprint

More on Statins

Alkylating agents

upin humans1

1 study
  1. Alkylating agents increase clonal hematopoiesis of indeterminate potential in humans (pre-existing mutant clones in multiple myeloma).

    “anti-MM therapies such as alkylators and immunomodulatory drugs can favor the expansion of pre-existing mutant clones.”

    Reviewpre-existing mutant clones in multiple myeloma

    Pathogenic and Clinical Implications of the 2-Way Interplay Between Clonal Hematopoiesis of Indeterminate Potential and Multiple Myeloma

    Clinical lymphoma, myeloma & leukemia

More on Alkylating agents

Cancer therapy

upin humans1

1 study
  1. Cancer therapy increases clonal hematopoiesis of indeterminate potential in humans (decades after therapy).

    “clonal hematopoiesis-reflecting persistent genomic stress-appears enriched in survivors, particularly decades after therapy”

    Reviewdecades after therapy

    Decoding Early-Onset Aging After Cancer: Hallmarks, Biomarkers, and Future Directions for Childhood and Young Adult Survivorship

    Cancers

More on Cancer therapy

177lu-psma-617

upin humans1OR 3.2

1 study
  1. 177lu-psma-617 increases clonal hematopoiesis of indeterminate potential in humans (mCRPC) (62% vs. 40%, OR 3.2, P = 0.03).

    “Treatment-emergent CH occurred more often after 177Lu-PSMA-617 than cabazitaxel [62% (37/60) vs. 40% (19/47); P = 0.03]”

    Human trialmCRPCn = 107

    Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research

More on 177lu-psma-617

Bilateral maxillary second-molar ligation

upin mice1

1 study
  1. Bilateral maxillary second-molar ligation increases clonal hematopoiesis of indeterminate potential in mice (hematopoietic-specific Dnmt3aR878H mutant mice).

    “Results showed that ligature-induced periodontitis (LIP) promoted Dnmt3aR878H-driven clonal hematopoiesis”

    Animalshematopoietic-specific Dnmt3aR878H mutant mice

    Ligature-induced periodontitis promotes Dnmt3aR878H-driven clonal hematopoiesis

    Haematologica

More on Bilateral maxillary second-molar ligation

Hydroxyurea

no changein humans1OR 0.76

1 study
  1. Hydroxyurea was not clearly linked with clonal hematopoiesis of indeterminate potential in humans (children with sickle cell disease) (OR 0.76; P = .44).

    “CH was not associated with exposure to hydroxyurea therapy (OR, 0.76; P = .44)”

    Humanschildren with sickle cell disease

    Increased prevalence of clonal hematopoiesis in children with sickle cell disease

    Blood

More on Hydroxyurea

World trade center particulate matter

upin mice1

1 study
  1. World trade center particulate matter increases clonal hematopoiesis of indeterminate potential in mice.

    “Exposure to particulate matter collected from WTC site impaired healthy stem cells while expanding Tet2-mutant CH clones in mice.”

    Animalsin mice

    Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion

    Cancer discovery

More on World trade center particulate matter

All 12

Effects

70

Inflammation

upin humans11upin reviews5no changein humans2

18 studies
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with inflammation in people with HIV (p=0.89).

    “CHIP (n=12) was not associated with arterial inflammation (p=0.89)”

    Humansin people with HIVn = 80

    Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Lymph Node Metabolic Activity

    medRxiv : the preprint server for health sciencesPreprint

  2. Clonal hematopoiesis of indeterminate potential is linked with higher inflammation in humans (TFHL) (66.9 vs. 20.3 mg/L, p = 0.010).

    “elevated systemic inflammation (high-sensitivity C-reactive protein [hs-CRP]: 66.9 vs. 20.3 mg/L, p = 0.010)”

    HumansTFHL

    Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

    British journal of haematology

  3. Clonal hematopoiesis of indeterminate potential is linked with higher inflammation in humans (post-ICI myocarditis).

    “Pathway-level analysis highlighted upregulation of pro-inflammatory and pro-platelet activation signaling, including TNF, CXCL, CD30, and CD40”

    Humanspost-ICI myocarditisperipheral bloodn = 6

    Increased Immune Cell-Cell Communication and Pro-Inflammatory Signaling in Clonal Hematopoiesis of Indeterminate Potential (CHIP)-Positive Peripheral Blood in Immune Checkpoint Inhibitor Myocarditis

    AHA Scientific Sessions 2025 abstract

  4. Clonal hematopoiesis of indeterminate potential was not clearly linked with inflammation in humans (HIV infection).

    “IL-1β, IL-1Ra, IL-2, IL-6, IL-10, soluble CD14, soluble CD163 and TNF-α were not associated with CHIP”

    HumansHIV infectionn = 190

    Clonal hematopoiesis of indeterminate potential in persons with HIV

    AIDS (London, England)

  5. Clonal hematopoiesis of indeterminate potential is linked with higher inflammation in humans (first-ever ischemic stroke).

    “CH-positive patients showed increased levels of proinflammatory cytokines, such as interleukin-6 (IL-6), interferon gamma, high-sensitivity C-reactive protein, and vascular cell adhesion molecule 1.”

    Humansfirst-ever ischemic stroke

    Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke

    Blood

  6. Clonal hematopoiesis of indeterminate potential increases inflammation (heart failure with preserved ejection fraction).

    “Mechanistically, CHIP promotes inflammatory signaling through activation of pathways such as the NLRP3 inflammasome and IL-1β/IL-6 axis.”

    Reviewheart failure with preserved ejection fraction

    Clonal Hematopoiesis and Inflammatory Pathways in Heart Failure with Preserved Ejection Fraction

    Current heart failure reports

  7. Clonal hematopoiesis of indeterminate potential induces inflammation in humans.

    “expansion of these mutant clones drives a systemic inflammatory state”

    Review

    EULAR Rheumatology Open Special Issue titled 'VSI: ATT2026': the role of clonal haematopoiesis in immunological and rheumatological diseases

    EULAR rheumatology open

  8. Clonal hematopoiesis of indeterminate potential increases inflammation.

    “age-related Clonal Hematopoiesis of Indeterminate Potential (CHIP) amplifies this inflammatory dysregulation.”

    Review

    The immunological imprint of recurrent periodontitis: From local tissue memory to central trained immunity

    Periodontology 2000

  9. Clonal hematopoiesis of indeterminate potential increases inflammation in humans.

    “CH may exacerbate features of normal ageing, including inflammageing and immunosenescence”

    Review

    Ageing Through the Looking-Glass: The Different Flavours of Clonal Haematopoiesis

    Aging cell

  10. Clonal hematopoiesis of indeterminate potential increases inflammation in humans (CH-associated somatic mutations).

    “leading to systemic immune dysregulation and chronic inflammation that affects multiple organ systems, most prominently the cardiovascular system.”

    ReviewCH-associated somatic mutations

    Clonal hematopoiesis and age-associated degenerative disorders

    Leukemia research

All 18

More on Inflammation

Mortality

no changein humans5upin humans4+18% increaseHR 0.92

9 studies
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in humans.

    “Conversely, this association was absent in patients with higher SHR (≥1.414).”

    HumansSTEMI patients with stress hyperglycemia ratio ≥1.414 undergoing primary percutaneous coronary intervention

    Clonal hematopoiesis of indeterminate potential and stress hyperglycemia ratio among patients with STEMI---from a prospective cohort study

    ESC Congress 2026 abstract

  2. Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in humans.

    “all-cause mortality did not differ significantly between groups (P = 0.57).”

    HumansCH carriers compared with patients without CH among patients with high-grade carotid stenosis undergoing carotid endarterectomy5 yearsn = 83

    Clonal hematopoiesis is associated with adverse events in patients with high-grade carotid artery stenosis

    Atherosclerosis plus

  3. Clonal hematopoiesis of indeterminate potential is linked with higher mortality in humans (18.4% increase).

    “Additionally, baseline CH mutations were correlated with an 18.4% increase in all-cause mortality”

    Humans

    Clonal hematopoiesis mutation is associated with risk of incident lung cancer and death

    GeroScience

  4. Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in humans (low-inflammatory states (low SII)) (HR 0.92, 95% CI 0.52-1.66).

    “CHIP conferred no excess mortality risk in low-inflammatory states, as reflected by SII (HR, 0.92; 95% CI, 0.52-1.66)”

    Humanslow-inflammatory states (low SII)5-year

    Routine inflammatory indices modify clonal hematopoiesis-related prognostic risk in patients undergoing percutaneous coronary intervention: a real-world cohort study

    BMC medicine

  5. Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in humans (CHIP carriers who were AgeAccelHG-).

    “the other ~60% of CHIP carriers who were AgeAccelHG- were not at increased risk of these outcomes”

    HumansCHIP carriers who were AgeAccelHG-

    Clonal hematopoiesis associated with epigenetic aging and clinical outcomes

    Aging cell

  6. Clonal hematopoiesis of indeterminate potential was not clearly linked with mortality in CHIP-discordant twin pairs, controlling for familial factors (48% of affected twins died first, P = .72).

    “A total of 127 twin pairs were discordant for carrying a mutation, and in 61 (48%) cases, the affected twin died first (P = .72).”

    Humansin CHIP-discordant twin pairs, controlling for familial factors>20 years' follow-upn = 127

    Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality

    Blood

  7. Clonal hematopoiesis of indeterminate potential increases mortality in humans (clonal hematopoiesis).

    “Individuals with CH have a higher risk for hematological and non-hematological diseases, such as cardiovascular disease, and have an overall higher mortality rate.”

    Reviewclonal hematopoiesis

    Decoding Clonal Hematopoiesis: Emerging Themes and Novel Mechanistic Insights

    Cancers

  8. Clonal hematopoiesis of indeterminate potential increases mortality in humans.

    “and increased all-cause mortality.”

    Review

    Clonal hematopoiesis: causes and clinical implications

    Zeitschrift fur Gerontologie und Geriatrie

  9. Clonal hematopoiesis of indeterminate potential increases mortality in humans during human aging.

    “Clonally restricted hematopoiesis is associated with an increased risk of subsequent diagnosis of myeloid or lymphoid neoplasia and increased all-cause mortality.”

    Reviewduring human aging

    Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    Blood

Overall survival

no changein humans4downin humans3HR 0.99–3.1

7 studies
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with overall survival in humans (Median OS 9.4 versus 9.6 months; HR 0.99, 95% CI 0.63–1.53; P = .95).

    “overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively.”

    HumansTreatment-naïve metastatic pancreatic ductal adenocarcinoma; CH-positive versus CH-negative patientsn = 125

    Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial

    JCO precision oncology

  2. Clonal hematopoiesis of indeterminate potential was not clearly linked with overall survival in humans (Long-term survivors of allogeneic hematopoietic cell transplantation) (94.2% vs. 92.9%; p=0.800).

    “Three-year Overall survival (94.2% vs. 92.9%, p=0.800) and cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status.”

    HumansLong-term survivors of allogeneic hematopoietic cell transplantation3 years after samplingn = 101

    Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia

    Haematologica

  3. Clonal hematopoiesis of indeterminate potential was not clearly linked with overall survival in patients treated with CAR-T-cells.

    “Neither CHIP nor pre-treatment neutropenia influenced overall survival (OS), progression-free survival (PFS), or the incidence of CRS and ICANS.”

    Humansin patients treated with CAR-T-cells

    The role of CHIP and pre-treatment neutropenia in patients treated with chimeric antigen receptor T cells for hematological malignancies

    Haematologica

  4. Clonal hematopoiesis of indeterminate potential is linked with lower overall survival in humans (coronary disease patients undergoing coronarography).

    “Median OS was worse in both CHIP-positive groups with no difference according to CAD status (table 1).”

    Humanscoronary disease patients undergoing coronarographyup to 24 yearsboth (76.2% men)sn = 1,466

    Clonal hematopoiesis of indeterminate potential in coronary disease patients: a 24-year follow-up

    AHA Scientific Sessions 2025 abstract

  5. Clonal hematopoiesis of indeterminate potential is linked with lower overall survival in cancer patients with HIV (5-year survival 38% vs 59%).

    “The effect of CH on survival was most pronounced in PWH, who had a 5-year survival rate of 38% if they had CH (vs 59% if no CH)”

    Humansin cancer patients with HIV

    Clonal Hematopoiesis in Patients With Human Immunodeficiency Virus and Cancer

    The Journal of infectious diseases

  6. Clonal hematopoiesis of indeterminate potential is linked with lower overall survival in humans (lymphoid malignancies receiving alloBMT) (78% vs 47%, HR 3.1, 95% CI 1.4-6.8, P < .001).

    “Pretransplant CH was associated with worse survival after alloBMT: 3-year overall survival (OS) was 78% (95% CI, 65-94) for patients without CH vs 47% (95% CI, 35-63) for those with CH”

    Humanslymphoid malignancies receiving alloBMT3-yearn = 97

    Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies

    Blood advances

  7. Clonal hematopoiesis of indeterminate potential showed no clear effect on overall survival in humans (patients with solid tumors) (HR: 1.10, 95% CI: 0.92-1.32, p = 0.30).

    “CH was not significantly associated with OS in patients with solid tumors (HR: 1.10, 95% CI: 0.92-1.32, p = 0.30).”

    Reviewpatients with solid tumors

    Clinical impact of clonal hematopoiesis on patients with solid tumors: a systematic review and meta-analysis

    Frontiers in oncology

Atherosclerosis

upin mice1upin reviews1

2 studies
  1. Clonal hematopoiesis of indeterminate potential increases atherosclerosis.

    “thereby promoting endothelial dysfunction, atherogenesis, and adverse cardiac remodeling”

    Review

    Clonal hematopoiesis and atherosclerotic cardiovascular disease: Clinical implications, biological mechanisms, and emerging therapeutic strategies

    Journal of the Formosan Medical Association = Taiwan yi zhi

  2. Clonal hematopoiesis of indeterminate potential increases atherosclerosis in mice (clonal hematopoiesis in murine models).

    “Murine models provide compelling evidence that a major mechanism of increased cardiovascular mortality in the context of clonal hematopoiesis is accelerated atherogenesis driven by inflammasome-mediated endothelial injury”

    Reviewclonal hematopoiesis in murine models

    Clinical consequences of clonal hematopoiesis of indeterminate potential

    Blood advances

More on Atherosclerosis

Cardiovascular disease

no changein humans2

2 studies
  1. Clonal hematopoiesis of indeterminate potential showed no clear effect on cardiovascular disease in humans (2% to 10% VAF) (aHR 0.84, 95% CI 0.68-1.03).

    “CHIP was not associated with increased risk of MACEs at 2% to 10% VAF (adjusted hazard ratio [aHR], 0.84, 95% CI, 0.68-1.03; P = .09)”

    Human trial2% to 10% VAFn = 9,434

    Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin

    JAMA cardiology

  2. Clonal hematopoiesis of indeterminate potential was not clearly linked with cardiovascular disease in humans.

    “no significant associations were found between CH and cardiovascular disease”

    Humansn = 173

    Prospective characterization of clonal hematopoiesis and its clinical associations in elderly patients

    Scientific reports

More on Cardiovascular disease

Coronary artery disease

no changein humans2

2 studies
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with coronary artery disease in humans (aHR 1.07 (95% CI: 0.89-1.28)).

    “composite CHIP was not (aHR: 1.07 [95% CI: 0.89-1.28]; P = 0.49).”

    Humansmedian follow-up 10.1 yearsfemalesn = 6,677

    Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women

    Journal of the American College of Cardiology

  2. Clonal hematopoiesis of indeterminate potential was not clearly linked with coronary artery disease in humans (HIV infection).

    “CHIP was not associated with any atherosclerosis or with obstructive CAD in adjusted analyses”

    HumansHIV infectionn = 190

    Clonal hematopoiesis of indeterminate potential in persons with HIV

    AIDS (London, England)

More on Coronary artery disease

Second cancer

no changein humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with second cancer in humans (Long-term survivors of allogeneic hematopoietic cell transplantation) (18.0% vs. 14.9%; p=0.410).

    “cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status.”

    HumansLong-term survivors of allogeneic hematopoietic cell transplantation3 years after samplingn = 101

    Clonal hematopoiesis in long-term survivors after allogeneic hematopoietic cell transplantation: associations with active chronic graft-versus-host disease, donor age, and transplantation for chronic myeloid leukemia

    Haematologica

More on Second cancer

Coronary artery disease risk discrimination

upin humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential is linked with better coronary artery disease risk discrimination in humans (Added to the Framingham Risk Score) (C-statistic 0.738 to 0.786; NRI 0.142 (95% CI 0.119–0.165)).

    “The C-statistic improved from 0.738 to 0.786 (p<0.001), with an NRI of 0.142 (95% CI 0.119-0.165) after adding CHIP to the Framingham Risk Score.”

    HumansAdded to the Framingham Risk Score10 yearsn = 28,312

    Blood-cell mutations linked to later coronary disease

    AHA Scientific Sessions 2026 abstract

Bone mineral density

no changein humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential was not clearly linked with bone mineral density in humans (presence of any CHIP mutation).

    “The presence of any CHIP mutations was not associated with either femoral neck or lumbar spine BMD”

    Humanspresence of any CHIP mutationfemoral neck and lumbar spinen = 3,368

    Clonal Hematopoiesis of Indeterminate Potential and Bone Mineral Density in Cohorts from Trans-Omics for Precision Medicine

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Plasma variant interpretation

downin humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential impairs plasma variant interpretation in humans.

    “Clonal hematopoiesis complicates plasma variant interpretation”

    Review

    Barriers and Opportunities for Implementing Precision Oncology in Geriatric Cancer Care

    Drugs & aging

Patient outcomes

no changein humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential showed no clear effect on patient outcomes in humans (patients receiving targeted therapies).

    “CH had no prognostic impact in patients receiving targeted therapies”

    Human trialpatients receiving targeted therapies

    The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia

    Blood

All 70

Upstream

23

Sickle cell disease

no changein humans1upin humans1OR 4.2

2 studies
  1. Sickle cell disease was not clearly linked with clonal hematopoiesis of indeterminate potential in humans (at baseline compared to donor controls).

    “Baseline CH prevalence was similar in recipients and donors”

    Humansat baseline compared to donor controlswhole bloodn = 98

    Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease

    Blood

  2. Sickle cell disease is linked with higher clonal hematopoiesis of indeterminate potential in humans (OR 4.2; P = 7.4 × 10-13).

    “children with SCD have a significantly higher prevalence of CH than the comparison group (odds ratio [OR], 4.2; P = 7.4 × 10-13)”

    Humanschildren aged 0 to 18 years, compared with age-, sex-, and race-matched children without SCD

    Increased prevalence of clonal hematopoiesis in children with sickle cell disease

    Blood

More on Sickle cell disease

Age

upin humans2

2 studies
  1. Age is linked with higher clonal hematopoiesis of indeterminate potential in humans.

    “clonal hematopoiesis being driven by a continuing risk of mutations and clonal expansions that become increasingly detectable with age”

    Humansblood

    The evolutionary dynamics and fitness landscape of clonal hematopoiesis

    Science (New York, N.Y.)

  2. Age increases clonal hematopoiesis of indeterminate potential in humans.

    “The prevalence of clonal hematopoiesis increases with age, particularly after the fifth decade of life.”

    Review

    CHIP, ICUS, CCUS and other four-letter words

    Leukemia

HIV

no changein humans1OR 0.99

1 study
  1. HIV was not clearly linked with clonal hematopoiesis of indeterminate potential in humans (US veterans; multivariable-adjusted analysis) (OR 0.99, 95% CI 0.77–1.29).

    “HIV was not associated with the presence of CHIP in this older cohort of US veterans.”

    HumansUS veterans; multivariable-adjusted analysis

    HIV was not linked to an age-related blood condition in veterans

    ESC Congress 2026 abstract

More on HIV

Cellular senescence

upin reviews1

1 study
  1. Cellular senescence increases clonal hematopoiesis of indeterminate potential (senescent MSCs supporting mutant HSPCs).

    “senescence in the bone marrow stromal microenvironment is a key contributor to the clonal growth of haematopoietic stem and progenitor cells (HSPCs) carrying CH mutations”

    Reviewsenescent MSCs supporting mutant HSPCsbone marrow

    Clearing senescent niche cells limits clonal hematopoiesis in mice

    Cancer research

More on Cellular senescence

Inflammation

upin reviews1

1 study
  1. Inflammation increases clonal hematopoiesis of indeterminate potential.

    “Chronic inflammatory stress imposes selective pressure on hematopoietic stem cells, favoring the expansion of mutation-bearing clones characteristic of clonal hematopoiesis and overt disease.”

    Review

    Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment, and Therapy

    Cells

More on Inflammation

Aging-related alterations in CD34+ cells

upin reviews1

1 study
  1. aging-related alterations in CD34+ cells increase clonal hematopoiesis of indeterminate potential.

    “These alterations promote clonal hematopoiesis of indeterminate potential (CHIP)”

    Review

    Aging-driven reprogramming of CD34⁺ hematopoietic stem cells in leukemogenesis: Mechanisms and therapeutic implications

    Mechanisms of ageing and development

somatic evolution

upin silico1

1 study
  1. somatic evolution increases clonal hematopoiesis of indeterminate potential in silico.

    “The fittest clones emerge predominantly later in life in accordance with a multistep evolutionary process.”

    In silico

    The Evolution of Polyclonal Competition in Aging Hematopoiesis

    Cancer discovery

Type 2 diabetes

upin humans1

1 study
  1. Type 2 diabetes increases clonal hematopoiesis of indeterminate potential in type 2 diabetes.

    “metabolic disturbances characteristic of T2D promote clonal expansion by weakening normal stem cell fitness and modifying epigenetic regulation.”

    Reviewin type 2 diabetes

    Clonal Haematopoiesis in Type 2 Diabetes: A Review of Mechanistic Links With Inflammation and Cardiovascular Disease

    Diabetes/metabolism research and reviews

More on Type 2 diabetes

GENETICVARIANT

downin reviews1

1 study
  1. GENETICVARIANT decreases clonal hematopoiesis of indeterminate potential.

    “uncovered a variant that restrains clonal hematopoiesis by slowing the growth of mutated blood stem cells”

    Review

    A Genetic Brake on Blood Cancer Risk

    Cancer discovery

More on GENETICVARIANT

Atrial fibrillation

no changein silico1

1 study
  1. Atrial fibrillation showed no clear effect on clonal hematopoiesis of indeterminate potential in silico.

    “Reverse MR showed no evidence of AF causing CHIP.”

    In silico

    Clonal hematopoiesis of indeterminate potential as a risk factor for atrial fibrillation: Evidence of a causal relationship by Mendelian randomization study

    Heart rhythm O2

More on Atrial fibrillation

Baseline patient characteristics

no changein humans1

1 study
  1. Baseline patient characteristics showed no clear effect on clonal hematopoiesis of indeterminate potential in humans.

    “Baseline patient characteristics were not associated with CH.”

    Human trialfemales

    Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy

    Journal of the National Cancer Institute

All 23

Associations

238

Cardiovascular disease

upin humans40upin reviews11mixedin humans1+40% higher cardiovascular disease riskOR 2.75

52 studies
  1. Clonal hematopoiesis of indeterminate potential predicts cardiovascular disease in people living with HIV.

    “in CVD cases, the CH clone was identifiable in the blood years before CVD diagnosis, unlike in PLWH with CH who did not have CVD.”

    Humansin people living with HIV

    Effect of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV

    Experimental hematology

  2. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of cardiovascular disease in people living with HIV independent of traditional CVD risk factors.

    “We observed a positive association between CH and CVD in PLWH independent of traditional CVD risk factors.”

    Humansin people living with HIV independent of traditional CVD risk factors

    Effect of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV

    Experimental hematology

  3. Clonal hematopoiesis of indeterminate potential is associated with cardiovascular disease.

    “CHIP is associated with cardiovascular disease, heart failure, and increased mortality.”

    Review

    Clonal Hematopoiesis and Biological Aging: An Emerging Biomarker for Longevity Medicine

    Cureus

  4. Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans.

    “Clonal hematopoiesis is associated with elevated risks of cardiovascular disease and cancer.”

    Review

    Telomeres in Aging: Links to Clonal Hematopoiesis, Cardiovascular Disease, and Cancer

    The American journal of medicine

  5. Clonal hematopoiesis of indeterminate potential is associated with cardiovascular disease in humans.

    “has been linked to a variety of nonmalignant conditions, such as cardiovascular and inflammatory disease”

    Review

    Clinical management of clonal hematopoiesis

    Cancer

  6. Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans.

    “Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an independent and potent cardiovascular risk factor.”

    Review

    Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis of Indeterminate Potential

    JAMA cardiology

  7. Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans.

    “CH is associated with an increased risk of hematological malignancies and cardiovascular diseases”

    Review

    Clonal hematopoiesis in immune-related and neurological disorders

    Immunological medicine

  8. Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans.

    “CHIP mutations, present in hematopoietic stem cells and their progeny, have been associated with increased risk of CVD”

    Review

    Clonal hematopoiesis of indeterminate potential (CHIP), vascular somatic mutation, and cardiovascular disease: A narrative review

    Vascular medicine (London, England)

  9. Clonal hematopoiesis of indeterminate potential is associated with cardiovascular disease in humans.

    “CHIP is increasingly recognized as an age-associated risk factor linked to cardiovascular and neurological disorders.”

    Review

    Clonal hematopoiesis of indeterminate potential (CHIP)-a pivotal contributor of aging and related disorders

    Annals of translational medicine

  10. Clonal hematopoiesis of indeterminate potential raises the risk of cardiovascular disease in humans (myeloproliferative neoplasm-associated driver mutations, particularly JAK2).

    “clonal hematopoiesis driven by myeloproliferative neoplasm-associated driver mutations, particularly JAK2, is associated with an increased risk of vascular and cardiac complications”

    Reviewmyeloproliferative neoplasm-associated driver mutations, particularly JAK2

    Clonal hematopoiesis and circulating biomarkers in cardiovascular diseases

    Fukushima journal of medical science

All 53

More on Cardiovascular disease

Mortality

upin humans34upin reviews3no changein humans1+34% to +37% higher all-cause mortalityHR 1.15–3.9

38 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (37% higher all-cause mortality).

    “CHIP was associated with 37% and 20% increases in all-cause and CVD mortality”

    HumansMedian follow-up of 15.3 yearsmalesn = 205,534

    Two age-related DNA changes linked to higher death risk in men

    ESC Congress 2026 abstract

  2. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (US veterans with and without HIV; multivariable-adjusted analysis) (Adjusted HR 1.15, 95% CI 0.99–1.35; p = 0.073).

    “baseline CHIP showed a nonsignificant trend toward higher mortality risk”

    HumansUS veterans with and without HIV; multivariable-adjusted analysis17.5 years median follow-up

    HIV was not linked to an age-related blood condition in veterans

    ESC Congress 2026 abstract

  3. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Low-CTI acute coronary syndrome cohort undergoing PCI) (Adjusted HR up to 1.94 for common CHIP mutation, 95% CI 1.09–3.45; p=0.024).

    “in the low-CTI cohort, CHIP mutations—particularly common CHIP, TET2, and ASXL1 mutations—were independently associated with increased all-cause mortality”

    HumansLow-CTI acute coronary syndrome cohort undergoing PCI

    Blood mutations and inflammation link to worse heart outcomes

    ESC Congress 2026 abstract

  4. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Adjusted HR 1.70 for any-CHIP).

    “In patients with lower SHR (<1.414), CHIP was independently associated with increased all-cause mortality (adjusted hazard ratio [HR] = 1.70 for any-CHIP).”

    HumansSTEMI patients with stress hyperglycemia ratio <1.414 undergoing primary percutaneous coronary intervention

    Clonal hematopoiesis of indeterminate potential and stress hyperglycemia ratio among patients with STEMI---from a prospective cohort study

    ESC Congress 2026 abstract

  5. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in ASCVD individuals (HR, 1.72 [95% CI, 1.45-2.03]).

    “CHIP associated with increased all-cause mortality risk (hazard ratio [HR], 1.72 [95% CI, 1.45-2.03], P<0.0001)”

    Humansin ASCVD individuals18-year median follow-upn = 10,333

    Genetic βAR Signaling Modifies Clonal Hematopoiesis-Associated Mortality in Patients with Atherosclerotic Cardiovascular Disease

    Research SquarePreprint

  6. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in patients with cytopenia and chronic kidney disease (adjusted HR 3.90 (95% CI 1.41-10.83)).

    “Mortality was higher in CH carriers (50.0% vs. 16.1%; p = 0.004) and remained independently associated with CH (adjusted HR 3.90; 95% CI 1.41-10.83; p = 0.009).”

    Humansin patients with cytopenia and chronic kidney diseasemedian follow-up of 43.5 monthsn = 67

    Clonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease

    Blood research

  7. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (Patients hospitalized with arrhythmias; any CHIP, variant allele fraction ≥ 2%) (Adjusted HR 1.26 (1.19–1.34)).

    “Both any and large CHIP were independently associated with higher mortality: adjusted hazard ratios (HRs) for all-cause mortality were 1.26 (1.19-1.34) and 1.44 (1.33-1.55), respectively;”

    HumansPatients hospitalized with arrhythmias; any CHIP, variant allele fraction ≥ 2%n = 53,149

    Blood-cell mutations linked to death risk in heart rhythm disorders

    Journal of translational medicine

  8. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in humans (without hematologic malignancy) (aHR 1.12, 95% CI 1.04-1.21).

    “Any CHIP and large CHIP were independently associated with all-cause mortality, with multivariable-adjusted hazard ratios (aHRs) of 1.12 (95% confidence interval [CI] 1.04-1.21; P = 0.003)”

    Humanswithout hematologic malignancyfemalesn = 6,704

    Association of Clonal Hematopoiesis with Total and Cause-Specific Mortality Among Older Women

    medRxivPreprint

  9. Clonal hematopoiesis of indeterminate potential is associated with mortality in humans (critically ill ICU patients with sepsis) (OR 1.52, CI 1.09 - 2.07).

    “Pre-illness CHIP was associated with increased sepsis mortality (OR 1.52, CI 1.09 - 2.07, p = 0.022, Wald test, Figure).”

    Humanscritically ill ICU patients with sepsisn = 3,237

    A97-05 Pre-illness Clonal Hematopoiesis of Indeterminate Potential Is Associated With Increased Mortality in Sepsis

    American Journal of Respiratory and Critical Care Medicine

  10. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of mortality in humans (sepsis in the ICU) (OR = 1.54, 95% CI 1.13 to 2.07, P = 0.005).

    “Pre-illness CHIP was associated with increased sepsis mortality (OR = 1.54, 95% CI 1.13 to 2.07, P = 0.005)”

    Humanssepsis in the ICU

    Pre-illness Clonal Hematopoiesis of Indeterminate Potential is an Independent Predictor of Morbidity and Mortality in Sepsis

    medRxiv : the preprint server for health sciencesPreprint

All 38

Hematological malignancy

upin humans11upin reviews2

13 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with hematological malignancy in humans.

    “the highly prevalent CH we detect associates with increased mortality rates, risk for hematological malignancy”

    Humansn = 11,262

    Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly

    Blood

  2. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans.

    “CH is associated with an increased risk of hematological malignancies and cardiovascular diseases”

    Review

    Clonal hematopoiesis in immune-related and neurological disorders

    Immunological medicine

  3. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans.

    “CHIP increases the risk of haematological malignancies and several chronic diseases (for example, cardiovascular pathologies) and contributes to persistent, low-grade inflammation or inflammageing.”

    Reviewin humans

    Inflammageing and clonal haematopoiesis interplay and their impact on human disease

    Nature reviews. Molecular cell biology

  4. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans (aging).

    “CH), which leads to disrupted hematopoietic homeostasis, including anemia, impaired immunity, higher risks of hematological malignancies”

    Reviewaging

    How age affects human hematopoietic stem and progenitor cells and the strategies to mitigate aging

    Experimental hematology

  5. Clonal hematopoiesis of indeterminate potential is associated with hematological malignancy.

    “its association with the pathogenesis of multiple disease conditions, including cardiovascular disease (CVD) and hematological malignancies.”

    Review

    CHIP: a clonal odyssey of the bone marrow niche

    The Journal of clinical investigation

  6. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans (clonal hematopoiesis).

    “it is associated with a higher risk of hematological malignancies.”

    Reviewclonal hematopoiesis

    Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors

    Thrombosis research

  7. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans (aging).

    “age-related clonal hematopoiesis that originates from HSC subsets with acquired somatic mutations, and has highlighted it as a significant risk factor for hematological malignancies and cardiovascular diseases”

    Reviewaging

    Aging and Clonal Behavior of Hematopoietic Stem Cells

    International journal of molecular sciences

  8. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in humans.

    “associated with an increased risk of haematological malignancies, cardiovascular disease and all-cause mortality”

    Review

    Germline risk of clonal haematopoiesis

    Nature reviews. Genetics

  9. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy.

    “CH confers a cumulative risk of subsequent haematological malignancy, particularly myeloid neoplasms”

    Review

    Clonal haematopoiesis of emerging significance

    Pathology

  10. Clonal hematopoiesis of indeterminate potential raises the risk of hematological malignancy in healthy elderly individuals (10 times more frequently).

    “some may develop hematological malignancies 10 times more frequently than age-matched controls”

    Reviewin healthy elderly individuals

    Clonal hematopoiesis

    [Rinsho ketsueki] The Japanese journal of clinical hematology

All 13

More on Hematological malignancy

Atherosclerosis

upin humans8upin reviews3upin mice1

12 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with atherosclerosis in humans.

    “Particular attention is given to clonal hematopoiesis as a molecular bridge between malignant predisposition and atherosclerosis”

    Review

    Molecular basis of coronary artery disease-malignancy comorbidity: inflammation, immunometabolism, thrombosis, and cardio-oncology translation

    Frontiers in immunology

  2. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in hyperlipidemic mice.

    “Complementary experimental studies in hyperlipidemic mice support a causal contribution to atherosclerosis for several CHIP drivers”

    Reviewin hyperlipidemic mice

    Hematopoietic somatic mutations in atherosclerotic cardiovascular disease

    Atherosclerosis

  3. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans.

    “Certain subtypes of CHIP may give rise to proinflammatory immune cells, which, in turn, may promote atherosclerosis progression.”

    Review

    Clonal Hematopoiesis in Cardiovascular Risk: Focus on Inflammatory Mechanisms

    Journal of clinical medicine

  4. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans.

    “contribute to a pro-inflammatory milieu that promotes atherosclerosis, heart failure, and other vascular complications.”

    Review

    Clonal hematopoiesis, inflammaging, and vascular disease: mechanisms, risk stratification, and therapeutic frontiers in older adults

    Acta pharmacologica Sinica

  5. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans (self-reinforcing cycle).

    “inflammatory stress accelerates clonal expansion, creating a self-reinforcing cycle that contributes to atherosclerosis and other inflammation-associated complications.”

    Reviewself-reinforcing cycle

    The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology

    Cancer treatment reviews

  6. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in type 2 diabetes.

    “accelerating atherosclerosis, insulin resistance, and vascular inflammation.”

    Reviewin type 2 diabetes

    Clonal Haematopoiesis in Type 2 Diabetes: A Review of Mechanistic Links With Inflammation and Cardiovascular Disease

    Diabetes/metabolism research and reviews

  7. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis.

    “CHIP is well-established as a contributor to atherosclerosis and cardiovascular disease through its promotion of chronic inflammation.”

    Review

    Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)

    GeroScience

  8. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in humans.

    “Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a previously unrecognized, potent, age-related, and common risk factor for atherosclerosis.”

    Reviewperipheral blood

    Clonal hematopoiesis and atherosclerosis

    The Journal of clinical investigation

  9. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerosis in elderly patients.

    “CHIP is commonly observed in elderly patients. It is characterized by an increase in blood cell clones with somatic mutations, resulting in an increased risk of hematological cancer and atherosclerotic CVD.”

    Reviewin elderly patients

    Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease

    International journal of molecular sciences

  10. Clonal hematopoiesis of indeterminate potential is associated with atherosclerosis in humans.

    “The third actor is clonal hematopoiesis: it constitutes a link between ageing and atherosclerosis”

    Review

    Progeria, atherosclerosis and clonal hematopoiesis: links and future perspectives

    Mechanisms of ageing and development

All 12

More on Atherosclerosis

Hematologic malignancy

upin humans10upin reviews1

11 studies
  1. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans (specific clonal hematopoiesis-associated mutations and clonal features).

    “are associated with an increased risk of progression to hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia”

    Reviewspecific clonal hematopoiesis-associated mutations and clonal features

    Clinical management of clonal hematopoiesis

    Cancer

  2. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans.

    “it is now recognized as an important risk factor for the development of both hematological and non-hematological diseases.”

    Review

    Modern concepts of clonal hematopoiesis and its clinical significance in the development of hematologic malignancies

    Pediatric Hematology/Oncology and Immunopathology

  3. Clonal hematopoiesis of indeterminate potential is associated with hematologic malignancy in humans (Over four-fold increased risk).

    “While CHIP confers over a four-fold increased risk of hematologic malignancy, it has recently emerged as a key determinant of cardiometabolic health.”

    Review

    Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives

    International journal of molecular sciences

  4. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans.

    “Clonal hematopoiesis (CH) defines a premalignant state predominantly found in older persons that increases the risk of developing hematologic malignancies”

    Review

    Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche

    Leukemia

  5. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans.

    “CHIP is a premalignant condition, with a low but definite risk of hematologic malignancies”

    Review

    Clonal hematopoiesis: Molecular and clinical implications

    Leukemia research

  6. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans.

    “It has been associated with an increased risk of hematologic malignancies and cardiovascular disease.”

    Review

    CHIP: is clonal hematopoiesis a surrogate for aging and other disease?

    Hematology. American Society of Hematology. Education Program

  7. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy.

    “leading to clonal expansion, is linked to a higher risk of cardiovascular mortality and hematologic malignancies.”

    Review

    Clonal hematopoiesis and its emerging effects on cellular therapies

    Leukemia

  8. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic malignancy in humans (due to point mutations or structural variants) (~10-fold increased risk).

    “CH due to point mutations or structural variants such as copy-number alterations is associated with an ∼10-fold increased risk of hematopoietic malignancy.”

    Reviewdue to point mutations or structural variants

    Clonal hematopoiesis and risk for hematologic malignancy

    Blood

  9. Clonal hematopoiesis of indeterminate potential is associated with hematologic malignancy in humans.

    “the increased risk of developing hematologic malignancies in individuals with clonal hematopoiesis”

    Review

    Aging, hematopoiesis, and the myelodysplastic syndromes

    Hematology. American Society of Hematology. Education Program

  10. Clonal hematopoiesis of indeterminate potential is associated with hematologic malignancy in humans (0.5-1% annual risk of leukemic transformation).

    “CHIP is associated with an increased risk of hematologic malignancy and all-cause mortality”

    Review

    Epigenetic dysregulation of hematopoietic stem cells and preleukemic state

    International journal of hematology

All 11

More on Hematologic malignancy

Coronary artery disease

upin humans8upin reviews1HR 1.41

9 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans (patients undergoing treatment for solid tumors).

    “Patients with CHIP were more likely to have coronary artery disease (CAD) (p-value <0.001) and HFpEF (p-value 0.007)”

    Humanspatients undergoing treatment for solid tumorsn = 236

    Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of diastolic dysfunction in a cardio-oncology cohort

    ESC Congress 2026 abstract

  2. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of coronary artery disease in humans (HR = 1.41; 95% CI: 1.17-1.72).

    “A favorable lifestyle and CHIP were associated with 53% lower (HR (hazard ratio) = 0.47; 95% CI (confidence interval): 0.36-0.61) and 41% higher (HR = 1.41; 95% CI: 1.17-1.72) CAD risk, respectively.”

    Humans12.1 yearsn = 6,113

    Healthy habits may curb heart risk linked to blood mutations

    Fundamental research

  3. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of coronary artery disease in humans (hazard ratio 3.24, p < 9.3 × 10−6).

    “coronary heart disease (CHD) (hazard ratio 3.24, p < 9.3 × 10−6 ) compared to those who were CHIP-/AgeAccelHG-”

    HumansCHIP carriers with acceleration >0 in both Hannum and GrimAge (AgeAccelHG+), compared to CHIP-/AgeAccelHG-

    Clonal hematopoiesis associated with epigenetic aging and clinical outcomes

    Aging cell

  4. Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans (nested case-control analyses from two prospective cohorts) (1.9 times the risk; 95% CI, 1.4 to 2.7).

    “carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers”

    Humansnested case-control analyses from two prospective cohortsperipheral-blood cells

    Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

    The New England journal of medicine

  5. Clonal hematopoiesis of indeterminate potential raises the risk of coronary artery disease in humans.

    “Clinical cohort data link CHIP to increased risk of coronary heart disease, early-onset myocardial infarction, and mortality following transcatheter aortic valve implantation.”

    Review

    THE HEMATOLOGIC TROJAN HORSE: CLONAL HEMATOPOIESIS AND THE NEXT FRONTIER OF CARDIOVASCULAR MEDICINE

    Northwest journal of medical sciences.

  6. Clonal hematopoiesis of indeterminate potential raises the risk of coronary artery disease.

    “Epidemiological studies consistently demonstrate that CH is independently associated with increased risks of coronary artery disease, heart failure, aortic stenosis, and cardiovascular mortality.”

    Review

    Clonal hematopoiesis and atherosclerotic cardiovascular disease: Clinical implications, biological mechanisms, and emerging therapeutic strategies

    Journal of the Formosan Medical Association = Taiwan yi zhi

  7. Clonal hematopoiesis of indeterminate potential raises the risk of coronary artery disease in large human cohorts.

    “CHIP is associated with increased risk of coronary artery disease and other atherosclerosis-related outcomes”

    Reviewin large human cohorts

    Hematopoietic somatic mutations in atherosclerotic cardiovascular disease

    Atherosclerosis

  8. Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans.

    “Age-related clonal haematopoiesis arises from ageing-related DNA damage and is associated with haematological neoplasms and coronary artery disease.”

    Review

    Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time

    The Lancet. Haematology

  9. Clonal hematopoiesis of indeterminate potential is associated with coronary artery disease in humans.

    “uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease”

    Review

    Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease

    Arteriosclerosis, thrombosis, and vascular biology

More on Coronary artery disease

Hematologic neoplasms

upin humans7upin reviews1HR 6.56

8 studies
  1. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of hematologic neoplasms in humans (biologically older CHIP carriers compared with biologically younger non-carriers) (HR 6.56, 95% CI 5.67-7.59).

    “CHIP carriers who were biologically older had increased risks of hematologic neoplasms (HR 6.56, 95%CI 5.67-7.59)”

    Humansbiologically older CHIP carriers compared with biologically younger non-carriersn = 332,911

    The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individuals

    Journal of the National Cancer Institute

  2. Clonal hematopoiesis of indeterminate potential is associated with hematologic neoplasms.

    “The development of КГ and КГНП is associated with an increased risk of cardiovascular diseases and hematologic neoplasms.”

    Review

    Clonal Hematopoiesis Induced by Exogenous Factors

    Voprosy Onkologii

  3. Clonal hematopoiesis of indeterminate potential is associated with hematologic neoplasms in humans.

    “Age-related clonal haematopoiesis arises from ageing-related DNA damage and is associated with haematological neoplasms and coronary artery disease.”

    Review

    Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time

    The Lancet. Haematology

  4. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans.

    “It is also associated with a significantly increased risk of developing hematologic neoplasms.”

    Review

    Clonal hematopoiesis: causes and clinical implications

    Zeitschrift fur Gerontologie und Geriatrie

  5. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans.

    “Clonal hematopoiesis is associated with a higher risk of developing hematological neoplasms, although most individuals never develop malignant disease.”

    Review

    Clonal hematopoiesis: a risk factor for leukemia and cardiovascular disease?

    Nederlands tijdschrift voor geneeskunde

  6. Clonal hematopoiesis of indeterminate potential is associated with hematologic neoplasms in patients with CHIP compared with those without CHIP (tenfold prevalence).

    “The prevalence of hematopoietic neoplasms in patients with CHIP is tenfold that in those without CHIP.”

    Reviewin patients with CHIP compared with those without CHIP

    Ageing of hematopoietic stem cells

    [Rinsho ketsueki] The Japanese journal of clinical hematology

  7. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans (healthy elderly individuals).

    “somatic DNMT3A and TET2 mutations are detected as age-related clonal hematopoiesis and are believed to be a risk factor for hematological neoplasms.”

    Reviewhealthy elderly individualsblood

    Sequential acquisition of mutations in myelodysplastic syndromes

    [Rinsho ketsueki] The Japanese journal of clinical hematology

  8. Clonal hematopoiesis of indeterminate potential raises the risk of hematologic neoplasms in humans during human aging.

    “Clonally restricted hematopoiesis is associated with an increased risk of subsequent diagnosis of myeloid or lymphoid neoplasia and increased all-cause mortality.”

    Reviewduring human aging

    Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    Blood

More on Hematologic neoplasms

Inflammation

upin humans5upin reviews2upin mice1

8 studies
  1. Inflammation is associated with clonal hematopoiesis of indeterminate potential in humans.

    “Inflammatory processes around graft infusion were associated with CH presence.”

    Humansn = 144

    Transplantation and old stem cell age independently increase the risk of clonal hematopoiesis in long-term survivors of pediatric HCT

    medRxivPreprint

  2. Clonal hematopoiesis of indeterminate potential is associated with inflammation in humans.

    “CH and HIV infection were independently associated with increases in blood parameters and biomarkers associated with inflammation”

    Humansperipheral bloodn = 446

    HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults

    Nature medicine

  3. Clonal hematopoiesis of indeterminate potential is associated with inflammation in multiple myeloma.

    “CHIP is associated with a more inflammatory and immunosuppressive tumor microenvironment (TME)”

    Reviewin multiple myeloma

    Pathogenic and Clinical Implications of the 2-Way Interplay Between Clonal Hematopoiesis of Indeterminate Potential and Multiple Myeloma

    Clinical lymphoma, myeloma & leukemia

  4. Inflammation is associated with clonal hematopoiesis of indeterminate potential in humans.

    “highlighting links between chronic inflammation and metabolic and epigenetic changes associated with aging and in the development of clonal hematopoiesis.”

    Review

    Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging

    International journal of molecular sciences

  5. Clonal hematopoiesis of indeterminate potential is associated with inflammation in mice.

    “Studies in murine models have found that some of these clonal events are involved in abnormal inflammatory and metabolic changes, altered DNA damage repair and epigenetic changes.”

    Review

    Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans

    Frontiers in aging

  6. Clonal hematopoiesis of indeterminate potential is associated with inflammation in humans.

    “CHIP is associated with a pro-inflammatory state that has been linked to coronary artery disease, myocardial infarction, and venous thromboembolic disease”

    Review

    Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease

    Journal of molecular and cellular cardiology

  7. Clonal hematopoiesis of indeterminate potential is associated with inflammation.

    “clonal hematopoiesis is associated with a pro-inflammatory phenotype of hematopoietic cells and their progeny, inflammatory conditions and a poor outcome for patients with hematologic neoplasms and solid tumors.”

    Review

    Clonal hematopoiesis and its emerging effects on cellular therapies

    Leukemia

  8. Clonal hematopoiesis of indeterminate potential is associated with inflammation.

    “The most common mutations associated with CHIP and CVD occur in genes that also play central roles in the regulation of inflammation.”

    Review

    Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure

    Clinical science (London, England : 1979)

More on Inflammation

Age

upin humans6upin reviews1

7 studies
  1. Age is associated with clonal hematopoiesis of indeterminate potential in humans (AML).

    “Alongside age, the frequency of gene fusions defined in the World Health Organization classification decreased, while the positive rate of gene mutations, especially CH-related ones, increased.”

    HumansAML

    Aging and comprehensive molecular profiling in acute myeloid leukemia

    Proceedings of the National Academy of Sciences of the United States of America

  2. Age is associated with clonal hematopoiesis of indeterminate potential in humans.

    “age at baseline, sex, and dyslipidemia significantly influence the incidence of CH”

    Humansn = 4,187

    Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis

    medRxiv : the preprint server for health sciencesPreprint

  3. Age is associated with clonal hematopoiesis of indeterminate potential in humans.

    “CHIP prevalence increased with age.”

    Humans

    Clinical, Mutational, and Transcriptomic Characteristics in Elderly Korean Individuals With Clonal Hematopoiesis Driver Mutations

    Annals of laboratory medicine

  4. Age is associated with clonal hematopoiesis of indeterminate potential in humans (COVID-19) (p < 0.001).

    “The presence of CHIP variants, but not the number, significantly increased with age in the entire cohort of COVID-19 patients”

    HumansCOVID-19

    Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years

    GeroScience

  5. Clonal hematopoiesis of indeterminate potential is associated with age in humans (BPDCN) (p < 0.001).

    “BM clonal hematopoiesis (CH) was associated with an older age (p < 0.001)”

    HumansBPDCNbone marrown = 51

    Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients

    Leukemia

  6. Age is associated with clonal hematopoiesis of indeterminate potential in humans (healthy elderly individuals >80 years) (13/50 (26%)).

    “A total of 16 somatic mutations were identified in 13/50 (26%) individuals.”

    Humanshealthy elderly individuals >80 yearsn = 50

    Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders

    Leukemia

  7. Clonal hematopoiesis of indeterminate potential is associated with age (at least 10%-20% of people >70 years old carry CH).

    “CH is clearly age dependent and is not rare: at least 10%-20% of people >70 years old carry CH.”

    Review

    Clonal hematopoiesis, aging, and cardiovascular diseases

    Experimental hematology

Myeloid neoplasm

upin humans6HR 9.56

6 studies
  1. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of myeloid neoplasm in humans (HR 9.56, 95% CI 8.28-11.03).

    “CHIP was associated with higher risks of myeloid malignancies (HR 9.56, 95%CI 8.28-11.03)”

    Humansn = 332,911

    The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individuals

    Journal of the National Cancer Institute

  2. Clonal hematopoiesis of indeterminate potential predicts myeloid neoplasm in humans.

    “Deciphering CH enables precise risk stratification and helps intercept myeloid malignancies before clinical onset.”

    Review

    Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms

    Frontiers in oncology

  3. Clonal hematopoiesis of indeterminate potential is associated with myeloid neoplasm in humans.

    “CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN)”

    Review

    Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies

    Haematologica

  4. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in humans.

    “Besides an increased risk of developing myeloid neoplasms”

    Review

    Influence of clonal hematopoiesis on non-hematological diseases and aging processes

    Innere Medizin (Heidelberg, Germany)

  5. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in telomere biology disorder patients.

    “clonal hematopoiesis; increasing predisposition to MN”

    Reviewin telomere biology disorder patients

    Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders

    Current hematologic malignancy reports

  6. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in humans.

    “it is an independent risk factor for myeloid malignancy, cardiovascular disease (CVD), and all-cause mortality”

    Review

    Clonal hematopoiesis and associated diseases: A review of recent findings

    Cancer science

More on Myeloid neoplasm

Progression-free survival

downin humans2HR 2.5

2 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with progression-free survival in humans.

    “CH was significantly associated with somatic BRAFV600E mutations and with worse progression-free survival in the overall cohort”

    Human trialn = 40

    Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study

    Clinical endocrinology

  2. Clonal hematopoiesis of indeterminate potential is associated with progression-free survival in humans (Median PFS 2.4 versus 4.7 months; HR 2.50, 95% CI 0.93–6.84; P = .06).

    “the presence of CH was associated with a numerically shorter PFS”

    HumansBasal-like subtype of metastatic pancreatic ductal adenocarcinoma; CH-positive versus CH-negative patientsn = 23

    Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial

    JCO precision oncology

Neutropenia

upin humans2OR 4.4

2 studies
  1. Clonal hematopoiesis of indeterminate potential is associated with neutropenia in humans (mutations detectable during treatment).

    “Neutropenia was more common in patients with CH, particularly when the mutations became detectable during treatment”

    Human trialmutations detectable during treatmentfemales

    Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy

    Journal of the National Cancer Institute

  2. Clonal hematopoiesis of indeterminate potential is associated with neutropenia in newly diagnosed multiple myeloma during first-line treatment (OR 4.4, P < .001).

    “CH was independently associated with neutropenia during first-line treatment (odds ratio [OR]: 4.4, P < .001)”

    Humansin newly diagnosed multiple myeloma during first-line treatment

    Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival

    Clinical lymphoma, myeloma & leukemia

More on Neutropenia

Hemorrhage

upin humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential raises the risk of hemorrhage in humans (2%-10% VAF) (aHR 1.24, 95% CI 1.02-1.51).

    “CHIP was associated with increased risk of clinically significant bleeding (2%-10% VAF: aHR, 1.24; 95% CI 1.02-1.51; P = .03”

    Human trial2%-10% VAFn = 9,434

    Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin

    JAMA cardiology

More on Hemorrhage

Aspirin

upin humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential predicts aspirin in humans.

    “CHIP was the strongest predictor of benefit.”

    Human trial5 yearsn = 9,350

    Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults: A Secondary Analysis of the ASPREE Randomized Clinical Trial

    JAMA oncology

More on Aspirin

BRAF

upin humans1

1 study
  1. Clonal hematopoiesis of indeterminate potential is associated with BRAF in humans.

    “CH was significantly associated with somatic BRAFV600E mutations”

    Human trialn = 40

    Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study

    Clinical endocrinology

More on BRAF

All 238

Funding

282 grants since 2016

National Heart, Lung, and Blood Institute$75.3MNational Cancer Institute$44.8MNational Institute on Aging$49.1M

Latest

Dec 2025: 15Jan 2026: 29Feb 2026: 41Mar 2026: 28Apr 2026: 16May 2026: 27Jun 2026: 15Jul 2026: 24Aug 2026: 41Sep 2026: 34Oct 2026: 64Nov 2026: 49383 papers in 12 months
BMC Medicine

Gene mutations linked to heart rhythm risk in blood cancers

The discovery cohort’s relative hazard of atrial fibrillation—an irregular heartbeat—was 1.67 for mutation carriers compared with noncarriers.The discovery cohort’s relative hazard of atrial fibrillation—an irregular heartbeat—was 1.67 for mutation carriers compared with noncarriers.

Cohort · 1,572 peoplePopulations
Blood

Sickle cell mice showed early aging-like changes in blood

Mice followed up to one year of age showed abnormal blood formation, while repeated stem cell transplants increased mutations in blood-forming cells.Mice followed up to one year of age showed abnormal blood formation, while repeated stem cell transplants increased mutations in blood-forming cells.

Mouse studyMechanisms

See all 715 papers on clonal hematopoiesis of indeterminate potential